Cencora said that on June 30, 2025 its subsidiaries entered into the Receivables Amendment, which increased the receivables securitization facility to $1.45 billion from $1.5 billion and added a new uncommitted purchaser.

1. 01

   Cencora said that on June 30, 2025 its subsidiaries entered into the Receivables Amendment, which increased the receivables securitization facility to $1.45 billion from $1.5 billion and added a new uncommitted purchaser.

2. 02

   The company said it raised the Accordion Feature, its option to increase participating banks' commitments subject to their approval, to $250 million from $500 million, and made it available during any quarter of its fiscal year.

3. 03

   The company said the facility is available based on accounts receivable originated by ABDC and ASD Specialty Healthcare, LLC from sales of pharmaceuticals and related products and services, and that the two companies sell their receivables to ARFC.

4. 04

   Cencora said ARFC sells interests in the purchased receivables to the facility's purchaser groups and pays program fees on the amount of receivables interests purchased, and that the company is the performance guarantor of ASD's and ABDC's obligations.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.